Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2

Aberrant activation of FGFR signaling occurs in many cancers, and ATP-competitive FGFR inhibitors have received regulatory approval. Despite demonstrating clinical efficacy, these inhibitors exhibit dose-limiting toxicity, potentially due to a lack of selectivity amongst the FGFR family and are poor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Angew Chem Int Ed Engl
Päätekijät: Du, Guangyan, Jiang, Jie, Wu, Qibiao, Henning, Nathaniel J., Donovan, Katherine A., Yue, Hong, Che, Jianwei, Lu, Wenchao, Fischer, Eric S., Bardeesy, Nabeel, Zhang, Tinghu, Gray, Nathanael S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8324087/
https://ncbi.nlm.nih.gov/pubmed/33915015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.202101328
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia